Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España

Introduction and objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or more of these targeted treatments, based on different clinical criteria, a global vision of mAb pre...

ver descrição completa

Detalhes bibliográficos
Autores: Casas-Maldonado, F., Álvarez-Gutiérrez, F.-J., Blanco Aparicio, Marina, Domingo Ribas, C., Cisneros Serrano, C., Soto Campos, G., Román Bernal, B., González Barcala, Francisco Javier
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21837
Acesso em linha:https://portalcientifico.sergas.gal//documentos/64be34293bbfc602eae5bc56
http://hdl.handle.net/20.500.11940/21837
Access Level:acceso abierto
Palavra-chave:AS A Coruña
CHUAC
AS Santiago
CHUS
id ES_14caa87a67adba2f3a954e590fd81ade
oai_identifier_str oai:runa.sergas.gal:20.500.11940/21837
network_acronym_str ES
network_name_str España
repository_id_str
spelling Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en EspañaCasas-Maldonado, F.Álvarez-Gutiérrez, F.-J.Blanco Aparicio, MarinaDomingo Ribas, C.Cisneros Serrano, C.Soto Campos, G.Román Bernal, B.González Barcala, Francisco JavierAS A CoruñaCHUACAS SantiagoCHUSIntroduction and objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or more of these targeted treatments, based on different clinical criteria, a global vision of mAb prescription management in a large sample of hospitals is not well characterised in Spain. The objective was to give a global vision of mAb prescription management in a large sample of hospitals in Spain. Materials and methods: We used an aggregate data survey method to interview pulmonology specialists in a large sample of Spanish centres (90). The following treatment-related information was obtained on patients treated with mAbs: specific mAbs prescribed, treatment interruption, switch and restart and the reasons for these treatment changes. Results: mAb prescription was more frequent in females (13.3% females vs 7.4% males; p < 0.001). There were no differences in prevalence by hospital complexity level. In contrast, there were differences by geographical area. Omalizumab was the most prescribed mAb (6.2%), followed by mepolizumab (2.9%). Discontinuation of Omalizumab (due to a lack of effectivity) and switches from this mAb to mepolizumab were more frequent. Very few restarts to the first treatment were observed after a switch from ?2 mAbs. Conclusions: Omalizumab appeared as the most prescribed mAb in SUA but was also the most withdrawn; a specific and objective characterisation of patients with SUA, along with asthma phenotyping, and together with further evaluation of safety and effectiveness profiles, will lead to future progress in the management of SUA with mAbs.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/64be34293bbfc602eae5bc56http://hdl.handle.net/20.500.11940/21837reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Españolhttps://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/218372026-06-12T08:40:47Z
dc.title.none.fl_str_mv Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
title Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
spellingShingle Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
Casas-Maldonado, F.
AS A Coruña
CHUAC
AS Santiago
CHUS
title_short Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
title_full Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
title_fullStr Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
title_full_unstemmed Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
title_sort Patrones de tratamiento de anticuerpos monoclonales en pacientes con asma grave no controlada atendidos por neumólogos en España
dc.creator.none.fl_str_mv Casas-Maldonado, F.
Álvarez-Gutiérrez, F.-J.
Blanco Aparicio, Marina
Domingo Ribas, C.
Cisneros Serrano, C.
Soto Campos, G.
Román Bernal, B.
González Barcala, Francisco Javier
author Casas-Maldonado, F.
author_facet Casas-Maldonado, F.
Álvarez-Gutiérrez, F.-J.
Blanco Aparicio, Marina
Domingo Ribas, C.
Cisneros Serrano, C.
Soto Campos, G.
Román Bernal, B.
González Barcala, Francisco Javier
author_role author
author2 Álvarez-Gutiérrez, F.-J.
Blanco Aparicio, Marina
Domingo Ribas, C.
Cisneros Serrano, C.
Soto Campos, G.
Román Bernal, B.
González Barcala, Francisco Javier
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv AS A Coruña
CHUAC
AS Santiago
CHUS
topic AS A Coruña
CHUAC
AS Santiago
CHUS
description Introduction and objectives: The use of monoclonal antibody (mAb)-based therapies is becoming the new standard of care for severe uncontrolled asthma (SUA). Even though patients may qualify for one or more of these targeted treatments, based on different clinical criteria, a global vision of mAb prescription management in a large sample of hospitals is not well characterised in Spain. The objective was to give a global vision of mAb prescription management in a large sample of hospitals in Spain. Materials and methods: We used an aggregate data survey method to interview pulmonology specialists in a large sample of Spanish centres (90). The following treatment-related information was obtained on patients treated with mAbs: specific mAbs prescribed, treatment interruption, switch and restart and the reasons for these treatment changes. Results: mAb prescription was more frequent in females (13.3% females vs 7.4% males; p < 0.001). There were no differences in prevalence by hospital complexity level. In contrast, there were differences by geographical area. Omalizumab was the most prescribed mAb (6.2%), followed by mepolizumab (2.9%). Discontinuation of Omalizumab (due to a lack of effectivity) and switches from this mAb to mepolizumab were more frequent. Very few restarts to the first treatment were observed after a switch from ?2 mAbs. Conclusions: Omalizumab appeared as the most prescribed mAb in SUA but was also the most withdrawn; a specific and objective characterisation of patients with SUA, along with asthma phenotyping, and together with further evaluation of safety and effectiveness profiles, will lead to future progress in the management of SUA with mAbs.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/64be34293bbfc602eae5bc56
http://hdl.handle.net/20.500.11940/21837
url https://portalcientifico.sergas.gal//documentos/64be34293bbfc602eae5bc56
http://hdl.handle.net/20.500.11940/21837
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403756715573248
score 15,812429

Registos relacionados